स्विट्ज़रलैंड - इतालवी - Swissmedic (Swiss Agency for Therapeutic Products)

sandoz pharmaceuticals ag - nelarabinum - soluzione per infusione - nelarabinum 250 mg, natrii chloridum, acidum hydrochloridum aut natrii hydroxidum, aqua ad iniectabile q.s. ad solutionem pro 50 ml corresp. natrium 89.075 mg. - il trattamento di acuta lymphoblastischer leucemia a cellule t e lymphoblastischem cellule t linfoma - synthetika

स्विट्ज़रलैंड - इतालवी - Swissmedic (Swiss Agency for Therapeutic Products)

novartis pharma schweiz ag - midostaurinum - capsule molli - midostaurinum 25 mg, macrogolglyceroli hydroxystearas 415 mg, kapselhülle: gelatina, macrogolum 400, glycerolum (85 per centum), ethanolum anhydricum 83 mg, mono/di/triglycerida, aqua purificata, e 171, e 172 (flavum), e 172 (rubrum), e 307, drucktinte: e 120, hypromellosum, propylenglycolum, pro capsula. - mieloide acuta leucemia, mastocitosi sistemica - synthetika

इटली - इतालवी - AIFA (Agenzia Italiana del Farmaco)

dr. reddy s s.r.l. - bendamustina - bendamustina

यूरोपीय संघ - इतालवी - EMA (European Medicines Agency)

kite pharma eu b.v. - axicabtagene ciloleucel - lymphoma, follicular; lymphoma, large b-cell, diffuse - agenti antineoplastici - yescarta is indicated for the treatment of adult patients with diffuse large b cell lymphoma (dlbcl) and high-grade b-cell lymphoma (hgbl) that relapses within 12 months from completion of, or is refractory to, first-line chemoimmunotherapy. yescarta is indicated for the treatment of adult patients with relapsed or refractory (r/r) dlbcl and primary mediastinal large b cell lymphoma (pmbcl), after two or more lines of systemic therapy. yescarta is indicated for the treatment of adult patients with r/r follicular lymphoma (fl) after three or more lines of systemic therapy.

यूरोपीय संघ - इतालवी - EMA (European Medicines Agency)

astellas pharma europe b.v. - gilteritinib fumarate - leucemia, mieloide, acuta - agenti antineoplastici - xospata è indicato come monoterapia per il trattamento di pazienti adulti che hanno recidivato o refrattario leucemia mieloide acuta (aml) con una mutazione flt3.

स्विट्ज़रलैंड - इतालवी - Swissmedic (Swiss Agency for Therapeutic Products)

astellas pharma ag - gilteritinibum - compresse rivestite con film - gilteritinibum 40 mg ut gilteritinibi hemifumaras, mannitolum, hydroxypropylcellulosum, hydroxypropylcellulosum substitutum humile, magnesii stearas, Überzug: hypromellosum, talcum, macrogolum 8000, e 171, e 172 (flavum), pro compresso obducto. - akute myeloide leukämie (aml) - synthetika

स्विट्ज़रलैंड - इतालवी - Swissmedic (Swiss Agency for Therapeutic Products)

jazz pharmaceuticals switzerland gmbh - defibrotidum (hergestellt aus darmschleimhaut von schweinen) - concentrato per soluzione per infusione - defibrotidum (hergestellt aus darmschleimhaut von schweinen) 80 mg, natrii citras dihydricus, natrii hydroxidum, acidum hydrochloridum, aqua ad iniectabile q.s. ad solutionem pro 1 ml corresp. natrium max. 8.16 mg. - behandlung von schwerer hepatischer venooklusiver erkrankung bei hämatopoetischer stammzelltransplantation - biotechnologika